Navigation Links
Perrigo Announces Conclusion of the FDA Re-Inspection
Date:4/12/2011

ALLEGAN, Mich., April 12, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of Perrigo's Allegan facility. The FDA has informed Perrigo that, effective immediately, the Company has an acceptable regulatory status, such that any pending export license and ANDA applications from this facility will once again be eligible for review and approval.

Perrigo's Chairman and CEO Joseph C. Papa stated, "On behalf of Perrigo, I want to thank the FDA Detroit District for making the re-inspection of our facilities a priority and for working cooperatively with us to resolve the issues previously raised in the Warning Letter. We are convinced that this process has made us a better company by enhancing the quality of our affordable healthcare products for our customers."  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference
2. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
3. Perrigo Company to Present at the Citi 2011 Global Health Care Conference
4. Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma
5. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
6. Perrigo Announces Settlement of Rogaine® Foam Patent Litigation
7. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
8. Perrigo Company Announces Quarterly Dividend
9. Perrigo to Acquire Assets of Paddock Labs for $540 Million
10. Perrigo Company Will Release Second Quarter Fiscal 2011 Results on February 1, 2011
11. Perrigo Company to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... 12, 2017 CarpalAID is a revolutionary new product that ... Carpal tunnel syndrome affects more than 8 million people ... rate of men. The common methods of treating CTS are painful ... hand braces or gloves. ... CarpalAID is a clear patch worn on the ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)...  US medical equipment and supply demand is forecast ... Medical Equipment & Supplies: United States , ... increases in demand for medical services – driven in ... supported by gains in disposable personal income – will ... introductions will also drive sales as providers and patients ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking ... (ages 18 to 29), had at least one case of sunburn within the past year. ... causes people to ignore the issue. However, only recently have people become conscientious of the ...
(Date:7/24/2017)... ... ... Anyone who uses scales know they have limits; a small kitchen scale ... scale to dispense medication. The first example is an issue of capacity, while the ... important to have the right balance for the process. METTLER TOLEDO’s new white paper, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally ... on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an ... China. , The article by Zidor Aldama described the situation in which Chinese children ...
(Date:7/24/2017)... ... 2017 , ... Paul Vitenas, MD, FACS is excited to report that he ... attend Allergan’s recent meeting with their Plastics Advisory Board. As one of the top ... bringing a newly defined structure to the aesthetics market. Dr. Vitenas , along ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Magic Wand® Rechargeable, the ... for favorite sex toy. Created in collaboration with website Kinkly.com, the award was ... voted. The Magic Wand Rechargeable won in stiff competition from brands such as ...
Breaking Medicine News(10 mins):